Mandate

Vinge advises FSN Capital L.P. II et al. on divestment of the CTEK/Creator Group

June 09, 2011

Vinge is advising FSN Capital L.P. II et al. in connection with the divestment of the CTEK/Creator Group to Altor Fund III.

The CTEK/Creator group is the world’s premier manufacturer of advanced battery chargers, sold under inter alia the "CTEK" brand, and a provider of consulting services related to product development under the “Creator” brand. CTEK is, in addition to sales under its own brand, delivering battery chargers to well renowned brands such as Rolls Royce, Ferrari, Porsche, Bentley, Mercedes-Benz, BMW, Lexus, Lamborghini, Alfa Romeo, Audi, Corvette, Maserati, Scania and Yamaha.

Since the investment by FSN Capital L.P. II in April 2008, CTEK has experienced largely increased sales volumes as well as a largely increased EBITDA despite having made significant investments in sales & marketing, R&D and the overall organization.

Closing of the transaction is subject to applicable competition law approvals.

The Vinge team advising FSN Capital L.P. et al. includes partners Bo Adrianzon and Johan Göthberg and inter alia associates Johan Steen, Carolina Walther and Ulrich Ziche.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026